Arcturus Therapeutics is trading 7.6% higher at $14.31 as investors assess interim ARCT-810 OTC-deficiency data and the transition to its LUNAR 2.0 delivery platform.
- BTIG maintained a Buy rating while lowering its price target to $20 from $23, citing the platform shift.
- Biotechnology stocks and major indexes moved lower, contrasting with the company’s gain.
- The immediate catalyst remains Phase 2 data and anticipated regulatory clarity.